PRNewsWire
13 Jun 2026, 15:15 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Eli Lilly's first-in-class type II JAK2 inhibitor (AJ1-11095) showed a 70% response rate in both spleen volume reduction (SVR35) and symptom improvement (TSS50) in patients who failed previous therapies. — Strong efficacy data in a hard-to-treat patient population provides significant proof-of-concept for a new revenue stream and competitive advantage in oncology.
+0.60AJ1-11095 demonstrated a reduction in driver mutation variant allele frequency (VAF) in 21 out of 23 patients, a result uncommonly seen with existing type I inhibitors. — This suggests a differentiated mechanism of action that could position the drug as a superior clinical alternative to current standards of care.
+0.50The Phase 1 study reported a manageable safety profile with no dose-limiting toxicities and a 78% patient retention rate. — Positive safety data reduces the risk of clinical hold or failure as the drug moves into larger expansion cohorts.
+0.30Continue reading
6 related stories
Top 1 mover · tap to explore
Lilly is expanding the clinical program to investigate the drug in second-line myelofibrosis, high-risk polycythemia vera, and first-line myelofibrosis patients. — Expanding the target patient population increases the potential total addressable market (TAM) for the asset.
+0.20Which stocks this story touches
The company reported promising clinical activity and an encouraging safety profile for its first-in-class type II JAK2 inhibitor.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
